cas 76536-66-8|| where to buy 9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Product Name:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

IUPAC Name:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Packing Unit	Available Stock	Price($)	Quantity

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 76536-66-8 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:76536-66-8; Molecular Formula:C23H25N3O3; Melting Point:-; Smiles Code:COC1=CC2=C(C=C1OC)C1=CC(NC3=C(C)C=C(C)C=C3C)=NC(=O)N1CC2; Density:

: Catalog Number:CM1045836; Molecular Weight:391.47; Boiling Point:; MDL No:; Storage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Ensifentrine; Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).